-
Sector Analysis
NewPurified Terephthalic Acid (PTA) Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Purified Terephthalic Acid (PTA) Capacity & Capital Expenditure (Capex) Overview The Purified Terephthalic Acid (PTA) capacity was 121.23 million tonnes per annum (mtpa) in 2023 and will increase at an AAGR of more than 5% from 2023 to 2028. In 2023, Iran, Saudi Arabia, and Turkey were the leading countries in the Middle East accounting for the total PTA capacity in the region. Large-scale production of polyester fiber in these regions, using PTA, drives its increasing consumption. This fiber finds...
-
Sector Analysis
NewCaustic Soda Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Caustic Soda Industry Capacity & Capital Expenditure (Capex) Overview The caustic soda industry capacity was 102.23 million tonnes per annum (mtpa) in 2023 and will increase at an AAGR of more than 1% from 2023 to 2028. In 2023, China, the US, India, Germany, and Japan were the leading countries accounting for over 75% of the total caustic soda capacity. The high consumption of caustic soda in various sectors such as water treatment, metal processing, and domestic cleaning is driving...
-
Sector Analysis
NewPetrochemicals Capacity and Capital Expenditure Outlook by Region, Countries, Companies, Commodity, Projects and Forecast to 2030
Petrochemicals Capacity & Capital Expenditure (Capex) Overview The petrochemicals capacity was 2600.06 million tonnes per annum (mtpa) in 2023. Asia, the Middle East, and the Former Soviet Union are the top regions contributing to capacity additions in the upcoming years. In the Middle East, most capacity additions are in Iran while in FSU, the majority of capacity additions are in Russia. Petrochemicals Capacity and Capex Outlook, 2023-2030 (mtpa) Buy the Full Report for More Insights on Petrochemicals Capacity and Capex...
-
Sector Analysis
NewAcrylonitrile Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Acrylonitrile Industry Capacity & Capital Expenditure (Capex) Overview The acrylonitrile industry capacity was 9.55 million tonnes per annum (mtpa) in 2023. China, the US, South Korea, Japan, and Taiwan were the key countries accounting for most of the acrylonitrile capacity in 2023. The acrylonitrile industry capacity will garner an AAGR of more than 4% from 2023 to 2028. In terms of global Capex spending non acrylonitrile industry planned and announced projects, Asia will account for the largest regional share with...
-
Analyst Opinions
Net Zero by 2050 – Industrial Decarbonization Gains Momentum (Vol.2)
Net Zero by 2050 Overview Businesses and tech giants globally are focusing on low-carbon products, renewables, and EVs to achieve net zero emissions. Key sectors such as aerospace, automotive, and technology are advancing sustainability through innovations in hydrogen, EVs, fuel cells, and smart energy solutions among others. The “Net Zero by 2050” report outlines decarbonization-related deals value and volume trends, VC investment activity and geographic trends, and leading investors. The report also provides facts and figures related to climate change,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R-01 in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-01 in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-01 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: iNeo-Vac-R01 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R-01 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-01 in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-01 in Metastatic Pancreatic Cancer Drug Details: iNeo-Vac-R01 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R-01 in Gastrointestinal Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-01 in Gastrointestinal Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-01 in Gastrointestinal Tract Cancer Drug Details: iNeo-Vac-R01 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R-01 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-01 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-01 in Metastatic Colorectal Cancer Drug Details: iNeo-Vac-R01 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R-01 in Metastatic Bile Duct Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-01 in Metastatic Bile Duct Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-01 in Metastatic Bile Duct Cancer Drug Details: iNeo-Vac-R01 is...